Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTXNASDAQ:BPMCNASDAQ:ONCNASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$106.57+1.6%$100.58$76.53▼$131.49$25.62B1.29950,012 shs1.33 million shsBPMCBlueprint Medicines$127.96-0.2%$99.05$73.04▼$128.50$8.26B0.841.20 million shs4.73 million shsONCBeigene$269.63-2.5%$240.18$141.31▼$287.88$31.92B0.3451,056 shs391,727 shsSMMTSummit Therapeutics$19.78-1.9%$23.61$6.78▼$36.91$14.69B-1.063.64 million shs2.89 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech-0.51%-4.75%+11.03%+5.48%+7.16%BPMCBlueprint Medicines+0.20%+0.24%+28.98%+43.12%+20.79%ONCBeigene+5.38%+7.60%+23.05%+6.69%+27,652,999,900.00%SMMTSummit Therapeutics+2.96%+2.18%-18.08%-3.03%+144.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNTXBioNTech2.878 of 5 stars4.43.00.00.02.50.80.0BPMCBlueprint Medicines1.1757 of 5 stars2.22.00.00.02.60.80.6ONCBeigene1.3529 of 5 stars2.50.00.00.02.21.70.6SMMTSummit Therapeutics2.9198 of 5 stars4.43.00.00.02.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTXBioNTech 2.83Moderate Buy$138.2529.72% UpsideBPMCBlueprint Medicines 2.32Hold$129.351.09% UpsideONCBeigene 3.00Buy$319.0018.31% UpsideSMMTSummit Therapeutics 2.77Moderate Buy$35.0977.41% UpsideCurrent Analyst Ratings BreakdownLatest BPMC, ONC, BNTX, and SMMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025SMMTSummit TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell6/11/2025SMMTSummit TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform$12.006/5/2025BNTXBioNTechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$134.00 ➝ $145.006/5/2025BPMCBlueprint MedicinesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$102.00 ➝ $129.006/5/2025BPMCBlueprint MedicinesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$88.00 ➝ $129.006/4/2025BPMCBlueprint MedicinesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell ➝ Hold$83.00 ➝ $129.006/3/2025BPMCBlueprint MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$132.006/3/2025BNTXBioNTechTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$151.00 ➝ $155.006/3/2025BPMCBlueprint MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/3/2025BPMCBlueprint MedicinesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/3/2025BPMCBlueprint MedicinesCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTXBioNTech$2.75B9.33$4.58 per share23.25$92.17 per share1.16BPMCBlueprint Medicines$562.12M14.70N/AN/A$4.67 per share27.40ONCBeigene$4.18B7.64N/AN/A$37.10 per share7.27SMMTSummit Therapeutics$700K20,985.62N/AN/A$0.11 per share179.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTXBioNTech$1.01B-$3.40N/AN/AN/A-15.16%-2.35%-2.05%8/4/2025 (Estimated)BPMCBlueprint Medicines-$67.09M-$2.47N/A196.86N/A-13.19%-77.49%-20.84%7/30/2025 (Estimated)ONCBeigene-$881.71M-$3.72N/A379.767.73-25.94%-25.12%-14.95%N/ASMMTSummit Therapeutics-$614.93M-$0.34N/AN/AN/AN/A-85.42%-52.66%8/5/2025 (Estimated)Latest BPMC, ONC, BNTX, and SMMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025ONCBeigene-$0.71$1.22+$1.93$0.01$1.12 billion$1.12 billion5/1/2025Q1 2025BPMCBlueprint Medicines-$0.42-$0.74-$0.32$0.01$158.31 million$149.41 million5/1/2025Q1 2025SMMTSummit Therapeutics-$0.10-$0.09+$0.01-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNTXBioNTech$1.531.44%N/AN/A N/ABPMCBlueprint MedicinesN/AN/AN/AN/AN/AONCBeigeneN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTXBioNTech0.017.337.21BPMCBlueprint Medicines1.152.852.80ONCBeigene0.051.931.72SMMTSummit TherapeuticsN/A8.318.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTXBioNTech15.52%BPMCBlueprint MedicinesN/AONCBeigene48.55%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipBNTXBioNTech19.20%BPMCBlueprint Medicines4.21%ONCBeigene6.62%SMMTSummit Therapeutics84.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTXBioNTech3,080240.39 million193.71 millionOptionableBPMCBlueprint Medicines64064.58 million61.22 millionOptionableONCBeigene9,000118.38 million90.59 millionN/ASMMTSummit Therapeutics110742.67 million86.28 millionOptionableBPMC, ONC, BNTX, and SMMT HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 13 at 10:45 AM | accessnewswire.comPolianta Ltd Takes $1.17 Million Position in Summit Therapeutics Inc. (NASDAQ:SMMT)June 13 at 6:02 AM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Trading Up 5.1% - Time to Buy?June 12 at 4:58 PM | marketbeat.comThese 24 Stocks Are Ripe for a Short SqueezeJune 12 at 3:11 PM | schaeffersresearch.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 12 at 9:00 AM | prnewswire.comSummit Therapeutics (NASDAQ:SMMT) Rating Increased to Strong Sell at Leerink PartnrsJune 12 at 7:52 AM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Now Covered by Leerink PartnersJune 12 at 3:57 AM | americanbankingnews.comResearch Analysts Issue Forecasts for SMMT FY2026 EarningsJune 12 at 2:23 AM | americanbankingnews.comLeerink Partners Initiates Coverage of Summit Therapeutics (SMMT) with Underperform RecommendationJune 11 at 11:38 PM | msn.comMerck rival Summit draws a rare sell-equivalent ratingJune 11 at 6:37 PM | msn.comWhy Summit Therapeutics Stock Tanked TodayJune 11 at 6:01 PM | fool.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Here's WhyJune 11 at 12:30 PM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 11 at 9:00 AM | accessnewswire.comSummit Therapeutics (NASDAQ:SMMT) Earns Underperform Rating from Analysts at Leerink PartnersJune 11 at 8:24 AM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Up - Here's What HappenedJune 10 at 11:35 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 10 at 9:00 AM | globenewswire.comEquities Analysts Set Expectations for SMMT FY2026 EarningsJune 10 at 8:30 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 9, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJune 7, 2025 | prnewswire.comSummit Therapeutics Inc. (NASDAQ:SMMT) Receives $37.40 Average PT from AnalystsJune 7, 2025 | americanbankingnews.comSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Beaten-Down Stocks Trading 50% Below Their 52-Week HighsBy Leo Miller | May 27, 2025View 3 Beaten-Down Stocks Trading 50% Below Their 52-Week HighsTurbulence for Joby Shares: What's Behind the Recent Dip?By Jeffrey Neal Johnson | May 22, 2025View Turbulence for Joby Shares: What's Behind the Recent Dip?RKLB Breakout Fails Near Highs: Should Investors Be Concerned?By Ryan Hasson | June 11, 2025View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernBy Leo Miller | June 2, 2025View Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernPalantir Soars on Government Deals as Valuation Debate LingersBy Chris Markoch | June 3, 2025View Palantir Soars on Government Deals as Valuation Debate LingersBPMC, ONC, BNTX, and SMMT Company DescriptionsBioNTech NASDAQ:BNTX$106.57 +1.65 (+1.57%) Closing price 04:00 PM EasternExtended Trading$105.92 -0.65 (-0.61%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Blueprint Medicines NASDAQ:BPMC$127.96 -0.25 (-0.19%) Closing price 04:00 PM EasternExtended Trading$128.38 +0.42 (+0.32%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Beigene NASDAQ:ONC$269.63 -6.90 (-2.50%) As of 04:00 PM EasternBeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.Summit Therapeutics NASDAQ:SMMT$19.78 -0.38 (-1.88%) Closing price 04:00 PM EasternExtended Trading$19.76 -0.03 (-0.13%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
